NAMS Releases 2022 Guidelines for Hormone Therapy
Hormone therapy remains the most effective treatment for hot flashes and genitourinary syndrome of menopause.
Hormone therapy remains the most effective treatment for hot flashes and genitourinary syndrome of menopause.
Receiving HRT within 6 months of recorded COVID-19 diagnosis linked to reduction in mortality risk.
Airway symptoms may develop in menopausal women with no prior history of asthma following the initiation of hormone replacement therapy.
Transgender persons who present for gender-affirming hormone therapy may be at an elevated cardiovascular risk.
Study finds nurse practitioners should advocate for gender-affirming hormone therapy (GAHT) to alleviate depressive symptoms in transgender patients.
Unintended pregnancies were reported 7 times more often by patients who took antibiotics compared with those who took control medicines.
Several questions remain regarding the effect of COVID-19 infection and hypercoagulation in the management of patients taking oral contraceptives, estrogen therapy, and patients who are pregnant.
New study is the first focused analysis of bacterial diversity in the urogenital tract of postmenopausal women, according to investigators.
In recently menopausal women using hormone treatment, circulating levels of pituitary-ovarian hormones are associated with changes in white matter hyperintensities.
Cross-sex hormone therapy may have a negative effect on lipid profile and glucose levels in transgender men but not in transgender women.